Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma
Normal Tension Glaucoma
About this trial
This is an interventional treatment trial for Normal Tension Glaucoma focused on measuring Normal tension glaucoma
Eligibility Criteria
The identification of NTG was based on reproducible glaucomatous visual field defects, corresponding to typical ONH changes.
Unilateral or bilateral visual field loss (description as below) as determined by at least two consecutive automated static threshold perimetry tests.
One eye is randomly selected in the cases where both eyes are treated.
Inclusion criteria:
- age ranging from 45 to 75 years
- best-corrected visual acuity no worse than 20/30 Snellen equivalent
- optic nerve head cupping (i.e., a vertical cup-to-disc ratio of more than 0.6) and/or notching of neuroretinal rim, and/or retinal nerve fiber defects characteristic of glaucoma
- visual field loss (i.e., a localized defect with at least three adjacent nonedge points depressed >5 dB from the normal value, and a nucleus of at least one point depressed 10 dB from the normal value)
- repeated measurements of untreated IOP, which documented values less than 22 mmHg
- central corneal thickness ranging from 540 to 560 microns
- open-angle confirmed by gonioscopy
Exclusion criteria:
- active or chronic systemic diseases and/or concomitant assumption of any medication known to affect IOP, BP and/or HR
- corneal abnormalities preventing reliable applanation tonometry
- severe ocular trauma, ocular inflammation or infection, intraocular surgery or argon laser treatment or laser trabeculoplasty
- myopic or other fundus changes preventing reliable optic disc evaluation,
- visual field defects caused by nonglaucomatous disease
- history of allergy to the ingredients of Cosopt or Xalatan eye drops
Sites / Locations
- Seoul St. Mary's hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Arm 1
Arm 2
Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day